Keros Therapeutics (KROS) Tops Q1 EPS by 481c

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of $3.62, $4.81 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $211.25 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight